Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


18. June 2021 | 15:10 CET

MorphoSys, Biogen, Sierra Growth - What is next?

  • Investments
Photo credits: pixabay.com

Pharmaceutical stocks are a bit like that: Giants like Johnson & Johnson or Novartis have an extensive product portfolio and can cushion failures of individual products quite well. It is often a matter of life and death for smaller, specialized companies with every development. Just yesterday, this could be observed in the CureVac share after its Corona vaccine candidate only achieved an efficacy of 47% in the clinical 2b/3 phase. Within a very short time, it disintegrated the stock price. Meanwhile, biotech pioneer Biogen surprised with an unjustified share price rally, which, however, could come to an abrupt end after a new setback. The situation is different for MorphoSys. Its planned acquisition of Constellation Pharmaceuticals initially weighed heavily on the share price, but it holds exciting potential. And the Canadian mining Company Sierra Growth is operating in a completely different environment; however, it has a top opportunity to offer in the current inflationary environment and should not go unmentioned.

time to read: 4 minutes by Carsten Mainitz
ISIN: DE0006632003 , US09062X1037 , CA8263191055


 

Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author


MorphoSys - Slow but steady price recovery

One of the "stock market winners" of the last few days is the biopharmaceutical Company MorphoSys. The Germans, dedicated to discovering, developing, and marketing innovative antibody therapies against cancer and autoimmune diseases, had already announced on June 2 the planned acquisition of Cambridge, US-based Constellation Pharmaceuticals. The announcement initially led to a drop in the share price of almost 15% due to the immense purchase price. However, the stock has since slowly recovered. Now the cash offer to acquire the remaining shares has been made: the Munich-based Company is prepared to pay the shareholders of Constellation Pharmaceuticals USD 34 per share, or a total of around USD 1.7 billion. The offer is valid until July 14. The offer is subject to additional conditions, such as the tender of at least a majority of the shares, the observance of a waiting period, and other customary restrictions.

MorphoSys expects to complete the merger in the third quarter. With the acquisition of Constellation, the Martinsried-based Company hopes to fill its product pipeline with promising candidates. However, the Company is also entering new territory with the field of epigenetics, which has not previously been part of its research approach. Constellation's most advanced product to date is Pelabresib, an active ingredient against myelofibrosis, a rare form of bone marrow cancer. The experts at JPMorgan believe the drug has expected peak annual sales of USD 1.7 billion. However, the drug will not complete Phase 3 clinical trials until late 2022. While the experts at JPMorgan, who see only a 50% probability of success for Pelabresib and criticize delays in the launch of the blood cancer drug Monjuvi in the US, have downgraded the MorphoSys share to neutral. Their colleagues at Berenberg Bank take a much more positive view of the acquisition with a price target of EUR 140. The stock is a clear buy for the Hanseatic bankers. Courageous investors can take advantage of the current share price weakness of MorphoSys.

Sierra Growth - Exciting Micro Cap

There are different types of investors: some are long-term oriented and primarily overweight stocks that currently appear undervalued. Others focus mainly on blue chips and dividend stocks. And still others like the thrill and like to invest in companies that promise high profits in a short time. If you are currently looking for a stock from the last group, you should look at the junior exploration Company Sierra Growth Inc. Based in the Canadian province of British Columbia, the Company specializes in the exploration of gold, silver, copper and molybdenum projects in their absolute early stages. The Company has focused on two regions: the US state of Nevada and the Andean country of Peru. In Peru, the Company, until recently, held exploration rights to two properties near the capital Lima, Silviera and Española.

However, the rights for Silviera were sold to the Peruvian CIEMSA group for USD 1 million last October. Given the looming election victory of the Marxist-Leninist presidential candidate Pedro Castillo, who has already announced a massive tax increase for foreign mining companies, this was undoubtedly a good move. At any rate, the focus is currently on the Nevada region. Here, the Company is currently exploring three projects: Glitra/Sat, Mildred/B&C Springs and Betty East, all of which are located on the Walker Lane trend, which is historically known to be high-grade. The collection of 1,805 soil geochemical samples at 50m to 100m intervals was completed in late May. Results are expected by the end of June/early July at the latest. Therefore, this is the ideal time for fortune seekers to get in on the action. Should the soil samples imply significant mineral deposits, this can positively influence the Company's share price within a very short time. The stock is also traded in Frankfurt and is currently valued at around CAD 8 million.

Biogen - Protests and failures on the Alzheimer's front could end share price rally

Since the beginning of June, the Biogen share has shown a brilliant price rally; the price increase amounted to almost 60%. What happened? Despite a clear vote last November by an advisory panel to the US Food and Drug Administration (FDA) that Biogen's new Alzheimer's therapy, called "Aduhelm," was not proven effective, by a vote of 10 to 0 with one abstention, the FDA now granted approval. Although three advisory panel members subsequently resigned in protest against the decision, this first approval of a therapy in more than 18 years nevertheless boosted the market's share price fantasies. It is quite possible that this is now over.

On Wednesday, the Company had to concede that a second drug candidate against Alzheimer's, Gosuranemab, based on an anti-tau antibody, had not shown the required statistical efficacy in Phase 2 clinical trials. The Company announced that it would discontinue further research on the drug. Although Biogen currently has another drug candidate against Alzheimer's disease in a Phase 3 trial, there is now a distinct possibility that investors will first try to take profits from the share price rally. Although analysts' median price target is still just above the current price, the majority of them recommend "hold."


Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. October 2021 | 12:10 CET | by Carsten Mainitz

Formycon, Memiontec, Synlab - Act before it is too late!

  • Investments

When an unpredictable event occurs, humanity sees how powerless it is in the face of it. We saw this in the spring of last year with the outbreak of the Corona pandemic. Only since the approval of various vaccines has a normalization taken place. However, further, foreseeable problems are coming our way. According to expert forecasts, water demand will exceed supply by 40% as early as 2030. Some companies sense an opportunity to profit from the water shortage through novel technologies.

Read

14. October 2021 | 07:46 CET | by Stefan Feulner

SAP, Kleos Space, Ballard Power - Igniting like a rocket

  • Investments

The storage and processing of data will be one of the themes of our society for the coming years. Big Data will create scientific advances and innovations, increasing the competitiveness of both science and companies across industries. Already today, innovative startups are working on the processing of larger amounts of data using artificial intelligence. The potential is enormous, the predicted growth rates gigantic.

Read

11. October 2021 | 11:30 CET | by Armin Schulz

Allianz, wallstreet:online, Commerzbank - Quo vadis stock markets?

  • Investments

The markets are highly nervous at the moment. First, the Corona numbers went up again, then the Chinese real estate giant Evergrande was on the verge of collapse, and the supply chains are still not back in step. The result was falling indexes. That automatically leads to more fear, as the Fear and Greed Index also showed. Last week, the market calmed down slightly, and the fear index dropped from 27 to 34 points. In Germany, there is also the fact that more people have dabbled in equity investments due to a lack of interest rates. According to the Global Wealth Report, the purchase of securities grew by 65%. Many of the newly added shareholders know only rising stock markets. Consolidation would not hurt the market. On the other hand, there is hardly any alternative to investing money at the moment. It remains exciting.

Read